

Natasha Kekre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1626011/publications.pdf>

Version: 2024-02-01

66
papers

1,439
citations

394421

19
h-index

361022

35
g-index

70
all docs

70
docs citations

70
times ranked

2272
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. <i>Transplantation</i> , 2022, 106, 562-574.	1.0	7
2	Optimal Timing of Allogeneic Stem Cell Transplantation for Primary Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 189-194.	1.2	5
3	Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies. <i>Cytotherapy</i> , 2022, 24, 405-412.	0.7	6
4	Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2022, 101, 1861-1863.	1.8	1
5	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022, 28, 735-742.	30.7	114
6	Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies. <i>Cytotherapy</i> , 2022, 24, 979-989.	0.7	2
7	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2248-2260.	1.4	20
8	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
9	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	2.4	15
10	Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study. <i>Trials</i> , 2021, 22, 230.	1.6	7
11	Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial. <i>BMJ Open</i> , 2021, 11, e043929.	1.9	10
12	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	1.4	88
13	Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2021, 39, 448-464.	1.7	7
14	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. <i>BMJ Open</i> , 2021, 11, e046707.	1.9	2
15	Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 739-739.	1.4	12
16	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). <i>Blood</i> , 2021, 138, 430-430.	1.4	9
17	Alternative donor transplantation for acute myeloid leukemia in patients aged <50 years: young HLA-matched unrelated or haploidentical donor?. <i>Haematologica</i> , 2020, 105, 407-413.	3.5	23
18	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18

#	ARTICLE	IF	CITATIONS
19	Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study. <i>British Journal of Haematology</i> , 2020, 191, e14-e19.	2.5	1
20	Cyclophosphamide-Glucocorticoids versus Lenalidomide-Dexamethasone as Treatment for Multiple Myeloma at First Relapse after Autologous Stem Cell Transplantation – A Retrospective Analysis. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 43, 437-442.	0.2	0
21	Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials. <i>Research Involvement and Engagement</i> , 2020, 6, 61.	2.9	12
22	Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. <i>BMJ Open</i> , 2020, 10, e034714.	1.9	9
23	Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1298-1302.	2.0	14
24	A Rapid and Sensitive Nucleic Acid Amplification Technique for Mycoplasma Screening of Cell Therapy Products. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 393-399.	4.1	16
25	Total body irradiation (18% Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1454-1456.	2.4	2
26	Surgical Site Infection Affects Length of Stay After Complex Head and Neck Procedures. <i>Laryngoscope</i> , 2020, 130, E837-E842.	2.0	9
27	Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL). <i>Blood</i> , 2020, 136, 49-49.	1.4	38
28	Efficacy, Safety, and Practicality of Tacrolimus Monitoring after Bone Marrow Transplant: Assessment of a Change in Practice. <i>Canadian Journal of Hospital Pharmacy</i> , 2020, 73, 37-44.	0.1	0
29	A Systematic Review of Evidence Supporting the Use of Autologous Cell Vaccines in the Treatment of Hematological Malignancies. <i>Blood</i> , 2020, 136, 16-16.	1.4	0
30	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
31	Venous thromboembolism incidence in hematologic malignancies. <i>Blood Reviews</i> , 2019, 33, 24-32.	5.7	69
32	The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 285-291.	0.2	3
33	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. <i>Molecular Therapy - Oncolytics</i> , 2019, 14, 179-187.	4.4	16
34	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
35	Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. <i>Transfusion Medicine Reviews</i> , 2019, 33, 98-110.	2.0	124
36	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	5.2	52

#	ARTICLE	IF	CITATIONS
37	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	5.2	37
38	Are We Choosing Wisely With Autologous Hematopoietic Cell Transplantation Screening? The Utility of Pulmonary Function Testing Prior to Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 68-72.	0.4	2
39	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. <i>Blood</i> , 2019, 134, 3263-3263.	1.4	0
40	Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. <i>Blood Cancer Journal</i> , 2018, 8, 14.	6.2	3
41	Natural Killer Cell IFN γ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 3747-3754.	1.5	68
42	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2466-2470.	2.0	7
43	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018, 132, 817-817.	1.4	0
44	Complications and Toxicities Associated with Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: Single Center Experience. <i>Blood</i> , 2018, 132, 4624-4624.	1.4	0
45	Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?. <i>Blood</i> , 2018, 132, 5159-5159.	1.4	0
46	Provincial Disparities in Access to Allogeneic Transplant in Canada. <i>Blood</i> , 2018, 132, 4742-4742.	1.4	0
47	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.	3.5	31
48	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. <i>Haematologica</i> , 2017, 102, 1291-1298.	3.5	38
49	Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2096-2101.	2.0	27
50	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e019321.	1.9	16
51	ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. <i>Blood Advances</i> , 2017, 1, 573-576.	5.2	27
52	Impact of HLA Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. <i>American Journal of Hematology</i> , 2016, 91, 551-555.	4.1	42
53	Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1416-1423.	2.0	67
54	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1808-1815.	2.0	29

#	ARTICLE	IF	CITATIONS
55	Cord blood versus haploidentical stem cell transplantation for hematological malignancies. <i>Seminars in Hematology</i> , 2016, 53, 98-102.	3.4	17
56	Emerging drugs for graft-versus-host disease. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 209-218.	2.4	7
57	Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 123-130.	4.1	6
58	A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 4519-4519.	1.4	1
59	Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2016, 128, 5782-5782.	1.4	1
60	Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. <i>Blood</i> , 2014, 124, 334-343.	1.4	125
61	Is Cytomegalovirus Testing of Blood Products Still Needed for Hematopoietic Stem Cell Transplant Recipients in the Era of Universal Leukoreduction?. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1719-1724.	2.0	39
62	Modelling Improvements in Cell Yield of Banked Umbilical Cord Blood and the Impact on Availability of Donor Units for Transplantation into Adults. <i>Stem Cells International</i> , 2013, 2013, 1-6.	2.5	1
63	The Impact of Prolonged Storage of Red Blood Cells on Cancer Survival. <i>PLoS ONE</i> , 2013, 8, e68820.	2.5	18
64	Spontaneous tumour lysis syndrome. <i>Cmaj</i> , 2012, 184, 913-916.	2.0	55
65	Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation. <i>Transfusion</i> , 2012, 52, 2049-2054.	1.6	9
66	Storage time of transfused red blood cells and impact on clinical outcomes in hematopoietic stem cell transplantation. <i>Transfusion</i> , 2011, 51, 2488-2494.	1.6	17